Search Result

Results for "

asthmatic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (1) Apoptosis (4) Autophagy (4) Calcium Channel (1) DNA/RNA Synthesis (1) Endogenous Metabolite (1) Ferroptosis (2) GABA Receptor (1) Glucocorticoid Receptor (3) GLUT (1) Histamine Receptor (1) HMG-CoA Reductase (HMGCR) (4) Interleukin Related (1) Isotope-Labeled Compounds (5) JNK (2) Leukotriene Receptor (11) MDM-2/p53 (2) Mitophagy (4) NF-κB (2) Opioid Receptor (1) Phosphatase (1) Phosphodiesterase (PDE) (1) Prostaglandin Receptor (3) Reactive Oxygen Species (2) Ser/Thr Protease (1) TRP Channel (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (6) Endocrinology (2) Inflammation/Immunology (28) Metabolic Disease (5) Neurological Disease (7)

By Targets:

Amylases (1)

Apoptosis (4)

Autophagy (4)

Calcium Channel (1)

DNA/RNA Synthesis (1)

Endogenous Metabolite (1)

Ferroptosis (2)

GABA Receptor (1)

Glucocorticoid Receptor (3)

GLUT (1)

Histamine Receptor (1)

HMG-CoA Reductase (HMGCR) (4)

Interleukin Related (1)

Isotope-Labeled Compounds (5)

JNK (2)

Leukotriene Receptor (11)

MDM-2/p53 (2)

Mitophagy (4)

NF-κB (2)

Opioid Receptor (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

Prostaglandin Receptor (3)

Reactive Oxygen Species (2)

Ser/Thr Protease (1)

TRP Channel (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (6)

Endocrinology (2)

Inflammation/Immunology (28)

Metabolic Disease (5)

Neurological Disease (7)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0283

Diacerein 1 Publications Verification Diacerhein; Diacetylrhein	Interleukin Related Calcium Channel	Inflammation/Immunology
Diacerein (Diacerhein), an orally active anthraquinone, reduces production of IL-1 converting enzyme then inhibits the activation of IL-1β by related downstream signaling. Diacerein is an anti-inflammatory and anti-rheumatic drug. Diacerein can relieve bronchospasm and control airway inflammation in asthmatic mice. Diacerein has the potential for slow acting drug in osteoarthritis (SYSADOA) research .

HY-107787

Dioxopromethazine Prothanon; 9,9-Dioxopromethazine; 9,9-Dioxypromethazin	Histamine Receptor	Inflammation/Immunology
Dioxopromethazine is an orally active antihistamine. Dioxopromethazine inhibits asthmatic symptoms .

HY-117616

Laurotetanine (+)-Laurotetanine	NF-κB	Cancer
Laurotetanine ((+)-Laurotetanine) is an potent and orally active isoquinoline alkaloid and could be extracted from the roots of Litsea cubeba (Lour.) Pers. Laurotetanine exerts an anti-asthmatic effect by inhibition of IgE, histamine, and inflammatory reactions via down-regulating MUC5AC and NF-κB signaling pathways .

HY-U00258

Minocromil

FPL59360
Others Inflammation/Immunology

Minocromil (FPL59360) is a new Anti-asthmatic agent.

Minocromil FPL59360	Others	Inflammation/Immunology
Minocromil (FPL59360) is a new *Anti-asthmatic* agent.

HY-116051A

16,16-Dimethylprostaglandin F2β 16,16-Dimethyl-PGF2β	Others	Cardiovascular Disease
16,16-Dimethylprostaglandin F2β (16,16-Dimethyl-PGF2β) is an analog of PGF2β (HY-12956B), which is an irratant, but prevents the aspecifically induced bronchospasm .

HY-B1718

Choline theophyllinate 2 Publications Verification Oxtriphylline	Endogenous Metabolite	Inflammation/Immunology
Choline theophyllinate (Oxtriphylline) is a choline salt of theophylline with anti-asthmatic activity .

HY-105999

APC 366	Ser/Thr Protease	Inflammation/Immunology
APC 366 is a selective inhibitor of mast cell tryptase (K_i=7.1 μM). APC 366 inhibits antigen-induced early asthmatic response (EAR), late asthmatic response (LAR), and bronchial hyperresponsiveness (BHR) in a sheep model of allergic asthma .

HY-U00412

Asthma relating compound 1

Others Inflammation/Immunology

Asthma relating compound 1 is an anti-asthmatic agent candidate extracted from patent EP0295656A1.
HY-N1399

Androsin

Others Inflammation/Immunology

Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth, with anti-asthmatic effects .

Asthma relating compound 1	Others	Inflammation/Immunology
Asthma relating compound 1 is an anti-asthmatic agent candidate extracted from patent EP0295656A1.

Androsin	Others	Inflammation/Immunology
Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth, with anti-asthmatic effects .

HY-153711

TRPA1-IN-2	TRP Channel	Inflammation/Immunology
TRPA1-IN-2 (compound 1) is a potent and orally active TRPA1 inhibitor with an IC₅₀ value of 0.04 µM. TRPA1-IN-2 shows anti-inflammation activity .

HY-17492

Zafirlukast 3 Publications Verification ICI 204219	Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-17492S

Zafirlukast-d7	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast-d₇ is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects[1][2].

HY-15234

Fluticasone furoate	Glucocorticoid Receptor	Inflammation/Immunology
Fluticasone furoate is a topical, intranasal, enhanced-affinity synthetic trifluorinated corticosteroid with a K_d of 0.3 nM. Fluticasone furoate has potent anti-inflamatory and anti-asthmatic activity, and low systemic exposure. Fluticasone furoate has the potential for allergic rhinitis treatment .

HY-17492S3

Zafirlukast-d6 ICI 204219-d₆	Leukotriene Receptor Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Zafirlukast-d₆ is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492R

Zafirlukast (Standard)	Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S1

Zafirlukast-13C,d3 ICI 204219-¹³C,d₃	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast- ¹³C,d₃ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S2

Zafirlukast-13C,d6 ICI 204219-¹³C,d₆	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast- ¹³C,d₆ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-119019

ASB14780

Phosphatase Inflammation/Immunology

ASB14780 is a 4-phenoxy derivative, the cytosolic Phospholipase A₂α (cPLA₂α) inhibitor, with an IC₅₀ value of 20 nM .

ASB14780	Phosphatase	Inflammation/Immunology
ASB14780 is a 4-phenoxy derivative, the cytosolic Phospholipase A₂α (cPLA₂α) inhibitor, with an IC₅₀ value of 20 nM .

HY-N7437

Akuammidine	Opioid Receptor DNA/RNA Synthesis	Neurological Disease Inflammation/Immunology
Akuammidine, isolated from the seeds of Picralima nitida, shows a preference for μ-opioid binding sites with K_i values of 0.6, 2.4 and 8.6 μM at μ-, σ- and κ-opioid binding sites, respectively. Akuammidine possesses anti-inflammatory and anti-asthmatic properties .

HY-131340

LASSBio-1632	Phosphodiesterase (PDE)	Inflammation/Immunology
LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion .

HY-15234S

Fluticasone furoate-d3	Isotope-Labeled Compounds Glucocorticoid Receptor	Inflammation/Immunology
Fluticasone furoate-d₃ is deuterium labeled Fluticasone furoate. Fluticasone furoate is a topical, intranasal, enhanced-affinity synthetic trifluorinated corticosteroid with a Kd of 0.3 nM. Fluticasone furoate has potent anti-inflamatory and anti-asthmatic activity, and low systemic exposure. Fluticasone furoate has the potential for allergic rhinitis treatment[1][2].

HY-B0774

Seratrodast 4 Publications Verification AA 2414	Ferroptosis JNK MDM-2/p53 Prostaglandin Receptor Reactive Oxygen Species	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity .

HY-15234R

Fluticasone furoate (Standard)	Glucocorticoid Receptor	Inflammation/Immunology
Fluticasone furoate (Standard) is the analytical standard of Fluticasone furoate. This product is intended for research and analytical applications. Fluticasone furoate is a topical, intranasal, enhanced-affinity synthetic trifluorinated corticosteroid with a K_d of 0.3 nM. Fluticasone furoate has potent anti-inflamatory and anti-asthmatic activity, and low systemic exposure. Fluticasone furoate has the potential for allergic rhinitis treatment .

HY-123801

MIDD0301 GL-II-93	GABA Receptor	Others
MIDD0301 (GL-II-93) is an orally effective, anti-asthmatic positive allosteric modulator of GABA_A receptor. MIDD0301 had no significant adverse immune reactions at repeated doses and was better than Prednisone (HY-B0214). MIDD0301 relaxes histamine contractions in guinea pig and human tracheal smooth muscle for the study of bronchial systolic diseases .

HY-13315

Montelukast sodium Maximum Cited Publications 8 Publications Verification MK0476	Leukotriene Receptor	Inflammation/Immunology
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-B0144A

Pitavastatin 5 Publications Verification NK-104	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-B0144B

Pitavastatin sodium NK-104 sodium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-13315A

Montelukast Maximum Cited Publications 8 Publications Verification MK0476 free base	Leukotriene Receptor	Inflammation/Immunology
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-B0774R

Seratrodast (Standard)	Ferroptosis JNK MDM-2/p53 Prostaglandin Receptor Reactive Oxygen Species	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Seratrodast (Standard) is the analytical standard of Seratrodast. This product is intended for research and analytical applications. Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity .

HY-13315B

Montelukast dicyclohexylamine MK0476 dicyclohexylamine	Leukotriene Receptor	Inflammation/Immunology
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .

HY-B0144

Pitavastatin Calcium 5 Publications Verification NK-104 hemicalcium; Pitavastatin hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-13315R

Montelukast sodium (Standard) MK0476 (Standard)	Leukotriene Receptor	Inflammation/Immunology
Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-13315AR

Montelukast (Standard)	Leukotriene Receptor	Inflammation/Immunology
Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-N0668

Rubusoside 2 Publications Verification	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .

HY-B0144R

Pitavastatin Calcium (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (Calcium) (Standard) is the analytical standard of Pitavastatin (Calcium). This product is intended for research and analytical applications. Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

Cat. No.	Product Name	Category	Target	Chemical Structure